-
Product Insights
IgA Nephropathy (Berger’s Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
IgA Nephropathy Clinical Trial Report Overview A total of 298 IgA Nephropathy clinical trials were conducted as of January 2024. The IgA Nephropathy clinical trial report provides a comprehensive understanding of the IgA Nephropathy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘IgA Nephropathy (Berger's Disease) - Drugs In Development, 2023’, provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Kidney Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Fibrosis - Drugs In Development, 2023’, provides an overview of the Kidney Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranous Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranous Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cystitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystitis - Drugs In Development, 2023’, provides an overview of the Cystitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2023
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2023’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Primary Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Primary Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nephrotic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Nephrotic Syndrome - Drugs In Development, 2023’, provides an overview of the Nephrotic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...